Issue link: https://www.e-digitaleditions.com/i/1022930
36 September 2018 Tablets & Capsules shell's permeability to air/oxygen. LFHCs don't require a plasticizer, so they provide better stability. Manufacturers can further improve stability with LFHCs by flushing the capsules with nitrogen and applying an airtight seal. Simplified development and manufacture LFHC manufacture essentially involves mixing the ingredients and filling the capsules, so it generally requires fewer processes and ingredients than other SODFs. This can speed up product development and launch, simplify technology transfer and scale-up, and reduce manufacturing space requirements. It can also reduce the size and weight of the drug product. Piascledine (Pharmascience) contains a mixture of avo- cado oil and soya oil and was initially marketed in France as a tablet that required five manufacturing steps. The product has since been changed to a LFHC, which requires only mixing and filling and is also smaller than the original tablet. Product differentiation, brand image, and counterfeit prevention Hard capsules can have a range of colors for both the capsule body and cap, and each can be preprinted around its circumference (360-degree printing). For example, ACG's Brandshield 4C hard capsules feature four-color circular-oriented printing (two colors on the capsule body and two colors on the cap) [5]. Because companies can print logos, brand names, and graphics right on the capsule, LFHCs provide excellent brand awareness and product differentiation. The printing also serves as an effective anti-counterfeiting measure. T&C References 1. Milin d K. B iyan i, "Ch o o sin g cap su les: A primer," Pharmaceutical Technology, Vol. 41, No. 10, pages 36-41. 2. Stephen Brown, Pharmaceutical composition com- prising nanocrystals, US Patent 9241940, Mw Encap Limited, Jan 26, 2016. 3. Geoff Rowley, "Filling of liquids and semi-solids into two-piece hard capsules," Pharmaceutical Capsules, Second edition, Fridrun Podczeck, Brian E. Jones, Eds., Pharmaceutical Press, 2004, pages 169-194. 4 . h t t p s : / / w w w . f d a . g o v / d o w n l o a d s / D r u g s / GuidanceComplianceRegulatoryInformation/Guidances/ UCM492172.pdf 5. http://www.acg-associatedcapsules.com/products/ index.php Milind K. Biyani is research and development director at Aspire Advisors, Mumbai, India (http://aspire-advisors.net/). He has more than 40 years of experience in dosage form devel- opment with various global and Indian pharmaceutical com- panies. He can be contacted at drmilind@aspire-advisors.net. Allendale, New Jersey Óä£ÈÓnÓääÊUÊÜÜÜ°À>iiÀÕðV `Ài°*iÌÀVJÀ>iiÀÕðV For 35 YEARS the pharmaceutical industry has relied upon ÀBiÀ to de-dust, de-burr and convey tablets with the highest efficiency. To learn more about how to *,"6 the EFFICIENCY of your tableting lines contact Kraemer U.S. Tablet de-dusting solutions from the Global Leader